Transformando la práctica clínica del paciente con Cáncer de Pulmón ALK positivo

Previous Page

Next Page

Page Background

Optimal First-Line Therapy for Advanced

ALK+ NSCLC

Crizotinib

Profile 1014

Ceritinib

ASCEND-3

1L

2L

11 months

18 months

(combined PFS)

Brigatinib

Ph 1-2

Alectinib

NP28673

Crizotinib

Profile 1014

Crizotinib

Profile 1014

24 months

(combined PFS)

21months

(combined PFS)

11 months

11 months